Comprehensive analysis of the global pipeline of small molecule antiviral compounds
The INTREPID Alliance’s bi-annual antiviral development landscape reports are a key contribution to the 100 Days Mission, whose aim is to be prepared in the future so that within the first 100 days of a new pandemic threat being identified, interventions can be made available, safe, effective, and affordable. INTREPID also periodically publishes special edition deep dive reports with analysis of highly relevant topics of interest.
Information in INTREPID’s Antiviral Toolbox is regularly updated and freely available to support policymakers, funders, and the global scientific community in identifying the most urgent needs and highest-impact opportunities in antiviral R&D.
View the current edition of the landscape report and available deep dives through the links below. Promising clinical and preclinical compounds in development are also available to investigate using INTREPID’s Interactive Pipeline.
Disclaimer
The INTREPID Alliance is a not-for-profit consortium of innovative biopharmaceutical companies and associations committed to accelerating antiviral research, aiming to ensure that we have a stronger pipeline and are better prepared to respond to future pandemic and endemic threats.
As part of our efforts, the INTREPID Alliance publishes and maintains the Antiviral Toolbox to be a non-promotional resource with the purpose of knowledge-sharing and to support better pandemic preparedness. The Antiviral Toolbox includes the Registry of Antiviral Compound Libraries, a registry of compound libraries designed to facilitate research. These registries are third-party resources and have been developed independently of, and at arm’s length, from INTREPID Alliance and its members. The INTREPID Alliance is not responsible for their content. The INTREPID Alliance also publishes and maintains a centralized list of promising investigational compounds. These compounds have been selected based on objective, scientific criteria, using publicly available sources, and at arm’s length from commercial influence of our member companies. See criteria listed in the report “Antiviral Clinical Development Landscape and Promising Clinical Compounds.” The designation of certain compounds as promising is based upon currently available information, and exclusively upon an assessment against these criteria. “Promising” is not a promotional claim. Candidate compounds have not been assessed by regulatory authorities to be safe and efficacious for the treatment of disease in humans. Our content is designed to be factual, informative, and non-commercial. It is not designed or intended to advertise or promote any pharmaceutical product or therapy or to advance the commercial interests of any company.